Revascularization via Cruciferous Metabolites:Sulforaphane Modulation of Endothelial Function in Erectile Dysfunction Models- Clinically Validated Actives from Blue Eyes Biotech
Title:
Revascularization via Cruciferous Metabolites:Sulforaphane Modulation of Endothelial Function in Erectile Dysfunction Models- Clinically Validated Actives from Blue Eyes Biotech
Mechanistic research demonstrates how sulforaphane (SFN) –the bioactive isothiocyanate derived from cruciferous glucosinolates – potentlyreverses vasculogenic erectile dysfunction in animal models. Key findingsreveal:
✅ 45%↑ Cavernosal NO Production via eNOS phosphorylation (vs. controls,p<0.01)
✅ Nrf2-Mediated Antioxidant Responsereducing ROS-induced endothelial damage
✅ Restored Endothelium-DependentVasodilation comparable to PDE-5 inhibitors
For nutraceutical and pharmaceuticalinnovators, this validates SFN as a clinically relevant vascular endotheliummodulator. Blue Eyes Biotech supplies high-bioavailability sulforaphane formats:
- Stabilized Sulforaphane-Lyzomes® (10%SFN, enteric release)
- Broccoli Sprout Extract (0.3% SFNequivalents, COSMOS certified)
- Custom Glucoraphanin/SFN Ratios fortargeted release profiles
Procurement Advantages:
•ProvenEfficacy in ED Models: Validated 5-10mg/kg/day oral dosing
•SynergisticFormulation Data: Enhanced effects with L-Citrulline and French Maritime PineBark
•StabilitySolutions: Nitrogen-flushed amber vials for SFN preservation
Regulatory-Ready Documentation:
- OECD 423 Acute Toxicity Reports (LD50>2000mg/kg)
- Residual Solvent Analysis (meets ICH Q3CClass 3)
- Non-GMO & Pesticide ResidueCertificates
Multi-Industry Applications:
➤Men's Health Supplements: Natural EDformulations targeting vascular etiology
➤Cardiovascular Nutraceuticals:Endothelial protectants for metabolic syndrome
➤Cosmeceuticals: Anti-redness serums viamicrocirculation enhancement
➤Pharmaceutical Intermediates: API forvascular repair drug development
Request Third-Party Efficacy Data:
